Pardes Biosciences is a clinical stage biopharmaceutical company that develops and commercializes novel therapeutics to improve the lives of patients with life-threatening diseases. Its lead candidate, PBI-0451, is in clinical development to treat and prevent severe acute respiratory syndrome coronavirus 2 infections. The company was founded in 2020 and is based in Carlsbad, California.